InterCure (NASDAQ:INCR – Get Free Report) posted its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $23.15 million during the quarter.
InterCure Price Performance
Shares of INCR opened at $0.89 on Friday. InterCure has a one year low of $0.68 and a one year high of $1.77. The company has a 50-day simple moving average of $0.79 and a two-hundred day simple moving average of $1.06. The firm has a market capitalization of $48.53 million, a PE ratio of 29.59 and a beta of 1.25.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of InterCure in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.
InterCure Company Profile
InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.
Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.
Featured Articles
Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.
